WO2024263130 - A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/263130
Publication Date
26.12.2024
International Application No.
PCT/TR2024/050639
International Filing Date
10.06.2024
Title **
[English]
A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
[French]
FORMULATION PHARMACEUTIQUE COMPRENANT DE LA LINAGLIPTINE, DE LA METFORMINE ET UN INHIBITEUR DE SGLT-2
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Esentepe Mahallesi Bahar Sokak
Ozdilek River Plaza Vyndham Grand No:13 Ic Kapi No:10
Sisli/Istanbul, TR
Inventors
MUTLU, Onur
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
ARI, Busra
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
SUNEL, Fatih
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
ATAK, Fadime Bilgehan
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
ATAMAN, Seval
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
YAZICI, Ozlem
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
SARP, Onder
Istinye Mahallesi Balabandere Caddesi No:14
34460 Sarıyer/Istanbul, TR
Priority Data
2023/007200
19.06.2023
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
Turkpatent
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1080 | |
| EPO | Filing, Examination | 4930 | |
| Japan | Filing | 533 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2635 |
Total: 9753 USD
Abstract[English]
The present invention relates to a pharmaceutical formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.[French]
La présente invention concerne une formulation pharmaceutique comprenant de la linagliptine ou des sels de celle-ci, de la metformine ou des sels de celle-ci et un inhibiteur de SGLT-2.